Floatz logo

FLUTICASONE

Chronic Phase Chronic Myelogenous Leukemia

Virginia Commonwealth UniversitySmall moleculePhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Chronic Phase Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB
su011248
OHSU Knight Cancer Institute
Phase 2B
Tas-102
National Cancer Institute (NCI)
Phase 2B
Deferasirox
City of Hope Medical Center
Phase 2CCC

View all 12 →

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Male Breast CancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →